Table 3.
Variable | Andexanet alfa n = 47 |
4F-PCC n = 37 |
---|---|---|
Demographics | ||
Age (years), mean ± SD | 77 ± 9 | 77 ± 10 |
Male, % | 51.4 | 51.4 |
Body mass index (kg/m2), mean ± SD | 28 ± 9 | 28 ± 6 |
Creatinine clearance (mL/min), mean ± SD | 73 ± 32 | 73 ± 48 |
Systolic blood pressure > 160 mm Hg, %a | 15.3 | 15.3 |
GCS score, %b | 14 ± 1 | 13 ± 2 |
Anticoagulant indication and medical history, % | ||
Anticoagulation indication, atrial fibrillation | 94.1 | 94.1 |
Medical history of heart failure | 22.3 | 22.3 |
Medical history of diabetes | 11.6 | 11.6 |
Medical history of myocardial infarction | 10.7 | 10.7 |
Medical history of stroke | 17.3 | 17.3 |
Concomitant use of an antiplatelet | 22.7 | 22.7 |
Intracranial hemorrhage characteristics | ||
Initial image to reversal start (hours), mean ± SD | 2.4 ± 1.9 | 2.4 ± 2.7 |
End of reversal to repeat image (hours), mean ± SD | 12.1 ± 1.2 | 12.1 ± 5.0 |
Traumatic onset, % | 30.8 | 30.8 |
Infratentorial location, % | 23.3 | 23.3 |
Initial intracerebral and/or intraventricular volume (mL), mean ± SD | 7.3 ± 9.8 | 7.3 ± 9.1 |
Reversal agent dosing, %b | ||
Andexanet alfa | ||
400 mg bolus + 440 mg infusion | 95.2 | – |
800 mg bolus + 860 mg infusion | 4.8 | – |
4F-PCC | ||
25 units/kg infusion | – | 86.1 |
50 units/kg infusion | – | 13.9 |
4F-PCC = four-factor prothrombin complex concentrate, GCS = Glasgow Coma Scale, SD = standard deviation
aBlood pressure reported was an average of the measurement at arrival and measurement just before reversal was administered
bNot included in propensity score